FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2331714508> ?p ?o ?g. }

• W2331714508 endingPage "675" @default.
• W2331714508 startingPage "674.3" @default.
• W2331714508 abstract "<h3>Background</h3> Combination therapy with biologics and synthetic disease-modifying antirheumatic drugs (sDMARD) is the standard treatment in patients with rheumatoid arthritis (RA) in which biologics are indicated. However, this is not always the case in daily clinical practice. The reasons and profile of patients on monotherapy have been poorly explored. <h3>Objectives</h3> To analyze the profile of RA patients treated with biologics in monotherapy and compare it with the standard combination treatment. <h3>Methods</h3> An observational cross-sectional study was conducted. Drug dispensation databases and patient clinical records from a tertiary hospital were reviewed. Patients with a clinical diagnosis of RA on any biologic in 2013 were selected for analysis. Demographic and clinical characteristics (age, gender, disease duration, rheumatoid factor status), reason for monotherapy and combination therapy with sDMARD were studied. Statistical comparison was performed by T-test and Chi-squared test. Disease activity was measured by DAS28 and multivariate analysis was used to evaluate the impact of individual parameters on DAS28. <h3>Results</h3> The analysis included 268 patients with RA treated with biologics. Monotherapy accounted for 11.2% of all patients. Patients on monotherapy showed a tendency without statistical significance to longer disease duration compared with combination therapy [15.8 (12.1) vs 13.6 (8.8); *p>0.05], similar age 62.6 (14.5) vs 62.1 (12.6), gender (female 90.0% vs 82.7%), and positive rheumatoid factor (77.8% vs 73.2%). Monotherapy was more frequent as third or later line of biological therapy (24.1% vs 8%; p<0.05). Among patients on monotherapy, Tocilizumab was the most frequently used agent (30%). Regarding to each individual biologic, monotherapy was more frequent in Tocilizumab (36%), and Abatacept (17.4%) than in anti-TNF (7-10%) patients. Reasons for monotherapy were sDMARD intolerance (60.9%) and contraindications (39.1%), such as lung disease (21.7%), liver disease (8.7%), neutropenia (4.3%), and pregnancy (4.3%). DAS28 was non-significantly greater in monotherapy than in combined therapy (p>0.05). Multivariate analysis showed higher DAS28 for third line or later biologic treatment but not for monotherapy (p=0.004). <h3>Conclusions</h3> Biologic monotherapy in RA is related to third or later line of treatment in clinical practice, being Tocilizumab the most frequently used medication for these patients. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3315" @default.
• W2331714508 created "2016-06-24" @default.
• W2331714508 creator A5000127704 @default.
• W2331714508 creator A5018306973 @default.
• W2331714508 creator A5037738055 @default.
• W2331714508 creator A5052603729 @default.
• W2331714508 creator A5065343738 @default.
• W2331714508 creator A5069339253 @default.
• W2331714508 creator A5085141195 @default.
• W2331714508 creator A5090825975 @default.
• W2331714508 date "2014-06-01" @default.
• W2331714508 modified "2023-09-26" @default.
• W2331714508 title "SAT0231 Analysis of Monotherapy with BIOLOGICS in Rheumatoid Arthritis in Daily Clinical Practice" @default.
• W2331714508 doi "https://doi.org/10.1136/annrheumdis-2014-eular.3315" @default.
• W2331714508 hasPublicationYear "2014" @default.
• W2331714508 type Work @default.
• W2331714508 sameAs 2331714508 @default.
• W2331714508 citedByCount "0" @default.
• W2331714508 crossrefType "journal-article" @default.
• W2331714508 hasAuthorship W2331714508A5000127704 @default.
• W2331714508 hasAuthorship W2331714508A5018306973 @default.
• W2331714508 hasAuthorship W2331714508A5037738055 @default.
• W2331714508 hasAuthorship W2331714508A5052603729 @default.
• W2331714508 hasAuthorship W2331714508A5065343738 @default.
• W2331714508 hasAuthorship W2331714508A5069339253 @default.
• W2331714508 hasAuthorship W2331714508A5085141195 @default.
• W2331714508 hasAuthorship W2331714508A5090825975 @default.
• W2331714508 hasConcept C126322002 @default.
• W2331714508 hasConcept C1862650 @default.
• W2331714508 hasConcept C198451711 @default.
• W2331714508 hasConcept C23131810 @default.
• W2331714508 hasConcept C2776232647 @default.
• W2331714508 hasConcept C2776999253 @default.
• W2331714508 hasConcept C2777575956 @default.
• W2331714508 hasConcept C38180746 @default.
• W2331714508 hasConcept C65409693 @default.
• W2331714508 hasConcept C71924100 @default.
• W2331714508 hasConceptScore W2331714508C126322002 @default.
• W2331714508 hasConceptScore W2331714508C1862650 @default.
• W2331714508 hasConceptScore W2331714508C198451711 @default.
• W2331714508 hasConceptScore W2331714508C23131810 @default.
• W2331714508 hasConceptScore W2331714508C2776232647 @default.
• W2331714508 hasConceptScore W2331714508C2776999253 @default.
• W2331714508 hasConceptScore W2331714508C2777575956 @default.
• W2331714508 hasConceptScore W2331714508C38180746 @default.
• W2331714508 hasConceptScore W2331714508C65409693 @default.
• W2331714508 hasConceptScore W2331714508C71924100 @default.
• W2331714508 hasIssue "Suppl 2" @default.
• W2331714508 hasLocation W23317145081 @default.
• W2331714508 hasOpenAccess W2331714508 @default.
• W2331714508 hasPrimaryLocation W23317145081 @default.
• W2331714508 hasRelatedWork W1491404397 @default.
• W2331714508 hasRelatedWork W1527365325 @default.
• W2331714508 hasRelatedWork W1978435955 @default.
• W2331714508 hasRelatedWork W1999301958 @default.
• W2331714508 hasRelatedWork W2023721760 @default.
• W2331714508 hasRelatedWork W2155117280 @default.
• W2331714508 hasRelatedWork W2410978906 @default.
• W2331714508 hasRelatedWork W2412341873 @default.
• W2331714508 hasRelatedWork W2912447547 @default.
• W2331714508 hasRelatedWork W3014312475 @default.
• W2331714508 hasVolume "73" @default.
• W2331714508 isParatext "false" @default.
• W2331714508 isRetracted "false" @default.
• W2331714508 magId "2331714508" @default.
• W2331714508 workType "article" @default.